Table 2. Cox Multivariate Regression Analysis in the European and Cancer Genome Atlas Cohorts for Single-Nucleotide Polymorphisms rs353630 and rs684559^a.

Cohort	European Cohort			Cancer Genome Atlas Cohort				Merged Cohort
Single-Nucleotide Polymorphism	No.	Hazard Ratio (95% CI)	P Value	No.	Hazard Ratio (95% CI)	P Value	Q Value	No.	Hazard Ratio (95% CI)	P Value
rs353630 (CD44)a
T/T	20	1 [Reference]	NA	6	1 [Reference]	NA	NA	26	1 [Reference]	NA
C/T	67	0.35 (0.19-0.65)	8.47 × 10−4	56	0.23 (0.07-0.70)	9.81 × 10−3	0.083	123	0.40 (0.23-0.66)	3.30 × 10−4
C/C	105	0.40 (0.22-0.72)	2.25 × 10−3	74	0.17 (0.06-0.51)	1.72 × 10−3	NA	179	0.39 (0.24-0.66)	1.30 × 10−4
C allele	172	0.38 (0.22-0.67)	8.76 × 10−4	130	0.19 (0.07-0.56)	2.74 × 10−3	0.045	302	0.40 (0.24-0.65)	1.20 × 10−5
rs684559 (CHI3L2)b
A/A	30	1 [Reference]	NA	18	1 [Reference]	NA	NA	48	1 [Reference]	NA
A/G	84	0.40 (0.24-0.66)	2.89 × 10−4	70	0.28 (0.12-0.61)	1.59 × 10−3	0.027	154	0.42 (0.28-0.63)	2.90 × 10−4
G/G	79	0.430 (0.26-0.72)	1.25 × 10−3	48	0.27 (0.12-0.61)	1.59 × 10−3	NA	127	0.45 (0.30-0.68)	1.25 × 10−3
G allele	163	0.41 (0.26-0.65)	1.75 × 10−4	118	0.27 (0.13-0.58)	7.80 × 10−4	0.026	281	0.44 (0.30-0.63)	2.00 × 10−4
Combined biomarker signaturec
Risk-indicating	47	1 [Reference]	NA	23	1 [Reference]	NA	NA	70	1 [Reference]	NA
Protective	148	0.37 (0.24-0.55)	1.30 × 10−6	113	0.20 (0.10-0.39)	4.20 × 10−6	NA	261	0.38 (0.27-0.53)	1.00 × 10−8

Abbreviation: NA, not applicable.

^aAll calculations were performed independently for each single-nucleotide polymorphism and adjusted for tumor stage (American Joint Committee on Cancer stages I through IV) and R status (ie, R0, R1, and R2).

^bThe rs353630 and rs684559 genotypes of 3 and 2 patients, respectively, were not determined succesfully in the European cohort.

^cThe risk-indicating genotypes were ones with the rs353630 T/T and/or rs684559 A/A genotypes; protective is defined by the presence of the rs353630 C allele and rs684559 G allele.